Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development
Intravacc, a global CDMO specializing in vaccines, has renewed its strategic partnership with biotech firm Primrose Bio to provide a seamless, end‑to‑end solution for conjugate vaccine development. The alliance leverages Primrose’s PeliCRM197® carrier protein, available in GMP‑grade milligram to kilogram quantities, alongside Intravacc’s expertise in antigen conjugation, scale‑up, and GMP production. Together they aim to fill a market gap for early‑stage developers needing reliable conjugation and manufacturing services. The partnership is positioned to accelerate vaccine pipelines and improve accessibility for researchers and industry clients.
Trump Signs Executive Order to Fast‑Track Psychedelic Research, Boosting Spiritual‑Based Therapies
President Donald Trump signed an executive order on April 18, 2026 that accelerates federal research into psychedelic medicines and awards priority review vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics. The move has ignited a surge in biotech stock...
Daraxonrasib Pill Doubles Survival in Advanced Pancreatic Cancer
An international Phase III trial found the oral KRAS inhibitor daraxonrasib doubled median overall survival for patients with metastatic pancreatic cancer, extending it from 6.6 to 13.2 months. The study also reported a lower rate of severe side‑effects, positioning the...
Laverock Therapeutics Awarded £2.2m Through Innovation Grants
Laverock Therapeutics has secured more than £2.2 million (approximately $2.8 million) in two competitive innovation grants to accelerate its programmable gene‑control platform. The first grant will fund scaling of a T‑cell product pipeline focused on solid‑tumour cancers, leveraging patient datasets and intracellular...
Agios Inks $165 M Global License Deal with Oscotec for ITP Drug Cevidoplenib
Agios Pharmaceuticals has signed an exclusive worldwide license agreement with Oscotec Inc. to develop and commercialize cevidoplenib, a next‑generation SYK inhibitor for immune thrombocytopenia. The deal includes a $25 million upfront payment and up to $140 million in development, regulatory and commercial...
Akeso Reports Overall Survival Benefit for Ivonescimab in Phase III Lung Cancer Trial
Akeso, Inc. disclosed that its investigational antibody ivonescimab achieved a statistically significant overall survival advantage in the Phase III HARMONi-6 study of advanced squamous non‑small cell lung cancer. The data, presented on June 1, 2026, revive expectations for Summit Therapeutics,...
Immunocore Posts Positive Phase 1/2 Data for Brenetafusp in Advanced Cutaneous Melanoma
Immunocore Holdings plc announced positive Phase 1/2 data for its PRAME‑targeted immunotherapy Brenetafusp in 66 patients with advanced cutaneous melanoma. Presented at the 2026 ASCO meeting, the early‑stage results suggest activity where current options are limited.
Why Breakthrough Cell and Gene Therapies Still Fail at the Finish Line
Nearly half of cell and gene therapy submissions now receive FDA complete response letters, with 42% flagged for deficiencies. The analysis shows that most of these CRLs arise from manufacturing, chemistry, and controls (CMC) issues rather than safety concerns. Shifts...
Blood DNA Test Can Spare Millions From Unnecessary Chemotherapy
The dream I pursued during my PhD in genomics was to use blood tests to determine whether patients would respond to extensive and expensive therapies before even starting them. We demonstrated this in autoimmune conditions and biological therapies. Now the same...
2026 Orphan Drugs Report: A Safe(r) Passage Amid Stormy Waters?
Orphan drug sales are on a steady climb, projected to represent over 21% of global prescription drug revenue by 2032—about $400 billion of an estimated $2 trillion market. The top eight orphan products will each exceed $6 billion in sales, with Darzalex leading...
Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026
Eli Lilly presented data from its phase III LIBRETTO‑432 trial of selpercatinib (Retevmo) as adjuvant therapy in early‑stage RET‑fusion positive NSCLC. In 151 patients, the drug reduced the risk of disease recurrence or death by 83% versus placebo, with 24‑month...
Photosynthes-Eyes: Spinach-Based Therapy Offers Hope for Dry Eyes
Scientists at the National University of Singapore have engineered a nanosized eye‑drop called LEAF, derived from spinach thylakoid membranes, that generates NADPH when exposed to ambient light. The 400 nm particles boost antioxidant production, rapidly normalising reactive oxygen species in cultured...
Akeso Presents the P-III (HARMONi-6) Trial Data on Ivonescimab + CT in 1L Squamous NSCLC at ASCO 2026
Akeso’s global Phase III HARMONi‑6 trial compared ivodescimab plus chemotherapy with Tevimbra plus chemotherapy in 532 patients with first‑line squamous non‑small cell lung cancer. The study met its primary overall‑survival endpoint, showing a 34% reduction in death risk (median OS 27.9 months...
Global Policy Gaps Slow Biosimilar Adoption and Access
A new UCSF study published in JAMA Health Forum reveals that biosimilar regulations vary widely across 19 countries, hindering their development and market uptake. While biologics represent only about 5% of prescriptions, they account for more than half of drug...
Justicia Carnea Extract Alleviates Oxidative Stress in Pancreatitis
Researchers evaluated ethanol extracts of Justicia carnea leaves in a mouse model of chronic pancreatitis induced by TNBS. Oral administration of 200 mg/kg or 400 mg/kg extract restored antioxidant enzyme levels, lowered oxidative stress markers, and preserved pancreatic glucagon expression. The higher...
Controversial Gene Therapy for Alzheimer’s Disease
Advanced Science News highlighted three breakthrough biotech applications. An AI‑powered wearable headband uses a brain‑computer interface and mindfulness cues to alleviate car sickness, reporting up to 60% symptom reduction. Researchers demonstrated vitrification techniques that preserve Anopheles gambiae mosquito larvae for...
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) From Phase I/II Study in Heavily Pretreated mCRPC...
MHB088C, a B7‑H3‑targeted antibody‑drug conjugate from Minghui Pharmaceutical, presented updated Phase I/II data in heavily pretreated metastatic castration‑resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. Among 59 enrolled patients, median radiographic progression‑free survival was not reached, with a...
ASCO26 HARMONi6 Updated – Plaudits, Pitfalls, and Pratfalls
Akeso Bio presented updated interim results from its HARMONi‑6 trial at ASCO 2026, eight months after the initial ESMO data. The new dataset, with longer follow‑up, revealed a modest overall response rate and emerging safety signals that fell short of...
Biohaven Looks to Obesity to Bounce Back From Run of Clinical and Regulatory Failures
Biohaven is repurposing its myostatin‑activin blocker taldefgrobep alfa for obesity after a failed Phase 3 spinal muscular atrophy trial. The drug showed weight‑loss benefits while preserving lean muscle and bone density, prompting a Phase 2 obesity study that began enrollment in March....
Daily Pill Doubles Survival Time for Pancreatic Cancer Patients
A phase III trial of the oral KRAS inhibitor daraxonrasib showed median overall survival of 13.2 months for advanced pancreatic cancer patients, roughly double the 6.6 months achieved with standard chemotherapy. The study enrolled 500 participants across North America, Europe...
Kelun‑Biotech Shows 87% Response Rate for RET‑Fusion Lung Cancer in Phase II ASCO Data
Kelun‑Biotech reported pivotal Phase II results for its next‑generation RET inhibitor lunbotinib fumarate at ASCO 2026, revealing an 87.1% objective response rate in pre‑treated patients and a 30% intracranial complete‑response rate. The data prompted the Chinese regulator to accept a...
HARMONi-6 Issues Persist, Lik
After listening to the updated HARMONi-6 readout at #ASCO26 many of the original issues are still holding up and may worsen over time...
Sacituzumab Tirumotecan + Pembrolizumab Cuts Progression Risk 65% in First‑Line NSCLC
Sichuan Kelun‑Biotech reported that its antibody‑drug conjugate sacituzumab tirumotecan combined with pembrolizumab cut the risk of disease progression by 65% in a Phase III trial of PD‑L1‑positive non‑small cell lung cancer. The data, presented at ASCO and published in The Lancet,...
Dizal Reports Breakthrough EGFR and JAK1 Data at ASCO 2026
Dizal presented compelling Phase II/III data on its fourth‑generation EGFR inhibitor DZD6008 and the JAK1‑only agent golidocitinib combined with anti‑PD‑1 at the 2026 ASCO meeting. The studies showed high tumor‑shrinkage rates, durable progression‑free survival and promising activity against brain metastases,...
Replimune Reports 3‑Year Survival Benefit for RP1 + Nivolumab in Anti‑PD‑1‑Resistant Melanoma
Replimune Group presented IGNYTE trial results at the 2026 ASCO meeting, showing a median overall survival of 32.9 months and nearly half of patients alive at three years. The RP1 plus nivolumab regimen delivered a 33.6% response rate with durable...
FDA Clears MannKind's Afrezza Inhalable Insulin for Kids 6+, Expanding Pediatric Diabetes Options
MannKind Corp. announced that the U.S. Food and Drug Administration has approved Afrezza inhalable insulin for children and adolescents aged six and older with type 1 or type 2 diabetes. The decision, based on the pivotal INHALE‑1 trial and two decades of...
This Discovery Could Change How Often You Need Ozempic Shots
A NIH team published in Nature Metabolism that semaglutide’s weight‑loss power depends on how long it sustains cyclic AMP (cAMP) spikes in the brain’s area postrema. Real‑time imaging of mouse neurons showed some cells keep elevated cAMP for hours while...
Long-Term Leukemia Trial Reveals MRD-Triggered Treatment May Slow or Prevent Relapse
The RELAZA2 trial has released its long‑term data, confirming that azacitidine administered at the first sign of measurable residual disease (MRD) can significantly delay relapse in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As the world’s first prospective MRD‑triggered...
Tempus Unveils the Next-Generation of Lens, Expanding Its Agentic AI Platform for Oncology Drug Development
Tempus AI launched the next‑generation Lens, an agentic AI platform that unifies its multimodal real‑world oncology data, high‑performance computing and validated AI agents. The cloud‑based system lets drug developers create research plans in plain language, execute analyses on more than...
New Pancreatic Cancer Drug Shows Survival Boost
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they...
Standing Ovation for Daraxonrasib Survival Benefit at ASCO26
Incredible #ASCO26 moment. Dr. Brian Wolpin, presenter of the daraxonrasib study, received a standing ovation DURING his talk after he stated the survival benefit for PDAC patients. It was sustained. Cheering. I have never see anything like it in the...
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported that its BRAFTOVI (encorafenib) regimen combined with cetuximab and FOLFIRI halved the risk of disease progression or death in patients with BRAF V600E‑mutant metastatic colorectal cancer. Median progression‑free survival more than doubled to 15.2 months versus 8.3 months for...
Kelonia Therapeutics Presents Updated First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in Vivo BCMA CAR-T Therapy at the...
Kelonia Therapeutics reported updated Phase 1 inMMyCAR data for its in‑vivo BCMA CAR‑T candidate KLN‑1010 at ASCO 2026. All 18 patients dosed showed a 100% overall response rate with MRD‑negative bone marrow, and the earliest‑treated patient remains disease‑free beyond ten months....
Bispecific T‑cell Engager Shows Promising Responses in Refractory
Just published @NatureMedicine and presented @ASCO Advanced, refractory solid cancers treated with a bispecific T cell engager (BiTE, Figure), Phase 1 trial, with or without Keytruda, in 61 patients. Some very favorable responses with "manageable safety profile" https://t.co/MkzQXY1psA
Lanatoside C Shows Senolytic Activity and Cuts Atherosclerosis in Mice
Researchers screened 2,150 FDA‑approved drugs and identified lanatoside C as a senolytic that eliminated senescent cells and lowered atherosclerotic plaque in mice, highlighting a new therapeutic avenue for age‑related vascular disease.
Eli Lilly's Retatrutide Triggers 30%+ Weight Loss in Late‑Stage Trial
Eli Lilly announced that its next‑generation GLP‑1 candidate Retatrutide produced weight loss of 30% or more in a late‑stage study, eclipsing results from existing injectables. The outcome could redefine the company's growth trajectory as it battles Novo Nordisk in the...
Pfizer’s TALZENNA‑XTANDI Combo Cuts Progression Risk 52% in HRR‑Mutated Prostate Cancer
Pfizer announced that its Phase 3 TALAPRO‑3 study found the TALZENNA (talazoparib) and XTANDI (enzalutamide) combination reduced radiographic progression or death by 52% versus XTANDI alone in men with HRR‑mutated metastatic castration‑sensitive prostate cancer. The data, presented with three‑year rPFS...
On KRAS Inhibitors and Why Potency Doesn’t Equal Durability
The latest ASCO data on second‑generation KRAS inhibitors reveal that higher potency does not automatically translate into longer patient responses. While first‑gen G12C agents such as sotorasib showed modest durability, new G12D compounds demonstrate improved binding but still face resistance...
Experimental Pill Promises New Hope for Deadly Pancreatic Cancer
Researchers reported that the experimental pill daraxonrasib, which blocks mutated KRAS proteins, nearly doubled median survival for patients with advanced pancreatic cancer to 13.2 months versus 6.7 months on chemotherapy. The drug showed fewer severe side effects and improved quality...
RASolute 302 Brings a “Transformative" Moment in Pancreatic Cancer: A 60% Improvement in Overall Survival
Revolution Medicines’ RASolute 302 phase‑3 trial showed that the RAS(ON) inhibitor daraxonrasib improved overall survival by 60% in patients with previously treated metastatic pancreatic ductal adenocarcinoma. Median overall survival more than doubled to 13.2 months versus 6.6 months on standard chemotherapy,...
STAT+: For Prostate Cancer Patients Set on Surgery, New Hormone Regimen May Improve Outcomes, Study Finds
A phase‑3 PROTEUS trial found that administering two hormone therapies before and after prostatectomy outperformed a single‑hormone regimen in high‑risk, early‑stage patients. The dual approach reduced biochemical recurrence and improved margin‑negative resection rates. Oncologists view the data as a potential...
Oculis' Phase 3 OCS-01 Eye‑Drop Trial Fails in Diabetic Macular Edema, Halts FDA Push
Oculis Holding AG announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops failed to meet the primary visual‑acuity endpoint and the key secondary 15‑letter gain endpoint in diabetic macular edema. The company will not pursue an...
NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO
NeuExcell Therapeutics announced that its first‑in‑human gene therapy NXL‑004 for recurrent malignant glioma earned a Rapid Oral presentation slot at ASCO 2026. The AAV‑NeuroD1 platform was tested in eleven patients, showing a favorable safety profile with no drug‑related serious adverse...
Retatrutide Is Bringing a Hard Look at Health Outcomes
Eli Lilly’s phase‑3 TRIUMPH‑1 trial showed retatrutide delivering unprecedented weight loss, with participants on the top dose shedding an average of 28.3% of body weight after 80 weeks and 45.3% achieving at least a 30% reduction. In a two‑year extension...
A Prodrug Approach for Activity‐Based Chemical Modulation Toward Multiple Pathological Targets in Alzheimer's Disease
Researchers have developed a pathology‑responsive prodrug platform that exploits elevated hydrogen peroxide in Alzheimer’s disease to release redox‑active aminophenols. The lead compound, BE‑1 remains inert until oxidative deboronation triggers its conversion, enabling simultaneous ROS scavenging and modulation of amyloid‑β aggregation,...
Weekly Reads: Effective LDL Gene Editing, Chinese Genetics Guidelines, Human Embryo Models in Space
A single‑infusion base‑editing drug (VERVE‑102) lowered LDL cholesterol in a small human study, sparking talk of a potential one‑time cure for high cholesterol. Parallel research unveiled universal transcriptomic aging clocks that can forecast mortality, advancing precision longevity metrics. Meanwhile, China...
Ivonescimab Plus Chemo Yields 71% Response In
Akeso ph2 trial of ivonescimab + chemo in 1L MSS/pMMR colorectal cancer (incl KRASm & w/t). ORR 71% (32/48). Via David Berz #ASCO26 $SMMT https://t.co/i5NW6fpKAu
Real-World Predictors of Survival and Response in Advanced Melanoma
Immunotherapy has transformed advanced melanoma care, yet many patients fail first‑line treatment. Researchers applied machine‑learning to a large, real‑world electronic health record database to build interpretable models for overall survival, progression‑free survival, and response. ECOG performance status, PD‑L1‑based first‑line therapy,...
HIV in South Africa: Why Rolling Out a Groundbreaking New Shot Will Miss a Critical Group of Men
The U.S. shipped the first batch of lenacapavir, a long‑acting injectable HIV‑prevention shot, to South Africa in early April 2026, with rollout slated for June. Clinical trials show close to 100% efficacy with just two doses per year. The national...
Lupin Wins FDA Nod for Generic Sutab Colon Prep, Targeting $132.8M Market
Lupin Limited has secured U.S. FDA approval for its generic version of Sutab colon‑preparation tablets, becoming the exclusive first‑to‑file applicant and earning a 180‑day exclusivity period. The product targets a market that generated roughly $132.8 million in U.S. sales in 2026,...